-
Case Studies
NewMountain Tourism – Case Study
Mountain Tourism Report Overview The mountain tourism case study offers detailed insights into the key destinations with opportunities and challenges faced by the industry. Mountains are important tourist destinations around the world and attract visitors for their picturesque beauty, sports attractions, and rich cultural and spiritual heritage. The expansion of transportation networks and digitalization has led to an increased interest in mountain tourism both for adventure and wellness. Mountain tourism allows tourists to witness and experience the environment in a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cannabidiol in Social Anxiety Disorder (SAD/Social Phobia) Drug Details:...
-
Product Insights
Opium Withdrawal Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium Withdrawal Syndrome - Drugs In Development, 2023’, provides an overview of the Opium Withdrawal Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium Withdrawal Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Social Anxiety Disorder (SAD/Social Phobia) - Drugs In Development, 2023’, provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Rett Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Rett Syndrome - Drugs In Development, 2023’, provides an overview of the Rett Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rett Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Drugs In Development, 2023’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TACH-101 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TACH-101 in Gastric Cancer Drug Details: TACH-101Â (formerly QC8222) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBX-2109 in Hypoparathyroidism
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBX-2109 in Hypoparathyroidism report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBX-2109 in Hypoparathyroidism Drug Details: MBX-2109 is under development for the treatment of...